Home » Healthcare » Cirrhosis Market

Cirrhosis Market By Etiology (Alcoholic Cirrhosis Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C) Autoimmune Cirrhosis Genetic and Metabolic Disorders-Related Cirrhosis) By Compensated vs. Decompensated Cirrhosis (Compensated Cirrhosis Decompensated Cirrhosis)-Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Price: $3699

Published: | Report ID: 21650 | Report Format : PDF

Market Insights

  • The global demand for cirrhosis was valued at USD 658.9 Million in 2022 and is expected to reach USD 915.71 Million in 2030, growing at a CAGR of 4.2% between 2023 and 2030.
  • The alcoholic cirrhosis segment is the market leader by etiology, accounting for more than 35% of total value in 2022, while the autoimmune cirrhosis segment is likely to grow rapidly in the estimated period.
  • Compensated cirrhosis is predicted to grow fastest during the projection period, while the decompensated cirrhosis segment has a market share of more than 58% in 2022.
  • The asymptomatic cirrhosis category dominated the global market with 55% of the total revenue share by clinical presentation segment.
  • With a significant market share of over 42% in 2022 and projections of high CAGR growth, the child-pugh score class B category will likely continue to dominate the need for the cirrhosis market globally.
  • The hospitals and clinics distribution channels segment dominates the global need for cirrhosis, accounting for more than 44% in 2022 and is predicted to expand at a high CAGR.
  • Over the projection period, the medications (antivirals, immunosuppressants) treatment approaches category is expected to expand at the highest rate, while the surgical interventions (liver transplantation) category dominates the market in 2022 with a 45% share.
  • North America is driving the growth of the cirrhosis industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 56% share in 2022. Europe held over 22% share in 2022.
  • Cirrhosis is a chronic liver condition characterized by replacing healthy liver tissue with scar tissue, leading to impaired liver function and potentially life-threatening complications.
  • The global cirrhosis market is driven by the rising prevalence of chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and viral hepatitis, major contributors to cirrhosis development.
  • The development of innovative pharmacological therapies targeting fibrosis and inflammation offers potential avenues for cirrhosis treatment and disease management.

Cirrhosis Market

Executive Summary

Market Definition

The cirrhosis market refers to the global healthcare sector that involves diagnosing, treating, and managing cirrhosis, a chronic liver condition characterized by progressive scarring and damage to liver tissue. Cirrhosis typically results from long-term liver injury and inflammation caused by various factors such as chronic alcohol abuse, viral hepatitis infections, non-alcoholic fatty liver disease, and autoimmune disorders. The market encompasses a range of medical interventions, therapies, and support services aimed at alleviating symptoms, slowing disease progression, preventing complications, and enhancing the overall quality of life for individuals affected by cirrhosis.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Overview

The global cirrhosis market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 4.2% between 2023 and 2030. The market was valued at USD 658.9 million in 2022 and is expected to reach USD 915.71 million in 2030.

The liver performs vital bodily activities, including protein synthesis, lipid and glucose metabolism, and detoxifying medications, alcohol, and environmental toxins. Liver disease is a wide term encompassing all potential issues that cause the liver to fail in its specific function. Cirrhosis, liver cancer, hepatitis, and liver abscess (pus collection) are various liver illnesses. Cirrhosis of the liver is a late stage of scarring caused by liver disease and illnesses such as prolonged alcoholism, hepatitis, and non-alcoholic fatty liver disorder. Abdominal pain, intestinal bleeding, exhaustion, jaundice, weakness, and weight loss are all signs of liver cirrhosis.

Alcoholic cirrhosis is a severe liver disease induced by excessive alcohol consumption. Cirrhosis of the liver affects 10% to 15% of alcoholics. As per the National Centre for Biotechnology Information (NCBI), nearly 2 billion people worldwide consume alcohol, with up to 75 million diagnosed with alcohol-use disorders and at risk of alcohol-related liver damage. The rising aging population, excessive alcohol consumption, and growing prevalence of liver diseases are the major factors driving the global cirrhosis market growth.

In recent years, changing lifestyles have significantly influenced growing alcohol consumption. The 2019 National Survey on Drug Consumption and Health shows that 14.1 million persons aged 18 and older have an alcohol consumption disorder. This number includes 8.9 million men and 5.2 million women. They also predict that 95,000 individuals die each year from alcohol-related causes.

Growing global awareness programs and increased R&D investment to discover novel therapeutic compounds are expected to boost the cirrhosis market over the coming years. However, stringent regulatory regulations, substantial investments necessary for drug research and development, and side effects associated with treatments recommended for liver cirrhosis hinder market expansion.

Segmentation by Etiology

  • The autoimmune cirrhosis segment is anticipated to witness the highest market CAGR in the forecast period, reflecting the growing prevalence of autoimmune liver diseases.
  • Alcoholic cirrhosis currently holds the largest global market share, accounting for over 35% in 2022, primarily due to the widespread occurrence of alcohol-related liver damage.

Segmentation by Compensated vs. Decompensated Cirrhosis

  • Compensated cirrhosis is expected to post the highest CAGR during the forecasted period, highlighting the importance of early diagnosis and intervention.
  • Decompensated cirrhosis currently leads the market share with over 58% share in 2022, emphasizing the need for advanced treatment options for patients with more severe conditions.

Segmentation by Clinical Presentation

  • The segment focusing on the symptoms of decompensated cirrhosis (ascites, variceal bleeding, hepatic encephalopathy, jaundice) is anticipated to register the highest CAGR over the projection period, indicating the demand for treatments addressing critical symptoms.
  • Asymptomatic cirrhosis, with a market share of nearly 55% in 2022, underscores the importance of proactive screening and management of liver diseases.

Segmentation by Disease Severity

  • Child-Pugh score class B dominates the global cirrhosis market, accounting for more than 42% in 2022 and is predicted to expand at a high CAGR, signaling the prevalence of moderate disease severity.
  • The rest of the demand for the cirrhosis market comes from Child-Pugh score class C, emphasizing the critical need for advanced treatments for patients with severe cirrhosis.

Segmentation by Distribution Channels

  • Hospitals and clinics are the dominant distribution channels, capturing more than 44% of the global cirrhosis market demand in 2022. This significant utilization reflects the specialized care and comprehensive treatment options available in these healthcare settings.
  • Retail and specialty pharmacies play a major role in addressing the remaining demand for cirrhosis solutions, ensuring accessibility to medications for patients.

Segmentation by Treatment Approaches

  • The surgical interventions (liver transplantation) category is the leading treatment approach, with a 45% share in 2022, emphasizing the significance of transplant procedures in advanced cirrhosis cases.
  • During the forecast period, the medications (antivirals, immunosuppressants) segment will grow fastest, driven by pharmaceutical therapies for cirrhosis management advancements.

Segmentation by Region

  • North America emerges as a remarkably profitable region for industry players in the cirrhosis market, holding a share of over one-third in 2022. The advanced regional healthcare infrastructure, well-established pharmaceutical industry, and increasing awareness about liver health contribute to its market dominance.
  • In 2022, Asia Pacific and Europe collectively accounted for just under 56% of the market share. With its robust pharmaceutical industry and healthcare system, Europe held over 22% share in the same year, reflecting a strong market presence.
  • The rest of the world, including regions like Latin America, the Middle East, and Africa, contributes to the remaining demand for cirrhosis solutions. This global distribution indicates the widespread impact of cirrhosis and the need for comprehensive healthcare solutions across diverse regions.

Cirrhosis Market regional analysis

The growing prevalence of acute and chronic liver disease and increased R&D of reliable diagnostic technologies to improve early diagnosis and patient outcomes are key factors propelling the cirrhosis market expansion.

North America has the largest share of the global cirrhosis market, with the U.S. contributing the most revenue. The region boasts advanced healthcare infrastructure, well-established pharmaceutical industries, and a high level of healthcare awareness among both healthcare professionals and the general population. The presence of cutting-edge medical facilities, research institutions, and a favorable regulatory environment facilitates the development, approval, and adoption of innovative cirrhosis treatment options. In addition, the region’s emphasis on research and development and substantial investments in healthcare technology and diagnostics contribute to the rapid identification, management, and treatment of cirrhosis cases.

The Asia Pacific region is expected to witness the highest growth rate in the cirrhosis market during the projected period. This growth can be attributed to several factors, including a large population base, increasing healthcare investments, improving healthcare infrastructure, and rising awareness about liver diseases. Besides, the changing regional lifestyle patterns, growing alcohol consumption, and a higher prevalence of hepatitis infections contribute to the rising cases of cirrhosis. Governments and healthcare organizations in Asia Pacific also focus on early diagnosis, better disease management, and increased availability of advanced treatment options, further driving the demand for cirrhosis-related therapies and medications.

The rising frequency of liver cirrhosis due to increased hepatitis infections is projected to propel the cirrhosis treatment industry. Hepatitis is a virus infection that causes liver inflammation. Hepatitis B & C are the most frequent illnesses that cause cirrhosis worldwide. Hepatitis A and D, on the other hand, are known to cause significant liver scarring in rare cases.

Cirrhosis is currently the 11th biggest cause of mortality worldwide, while liver cancer is the 16th major cause of death; together, these two diseases account for 3.5% of all global deaths. Also, the increase in government-led initiatives in liver cirrhosis treatments is another factor likely to accelerate the global market in the upcoming years.

Key Highlights of the Report

The global cirrhosis market is segmented by etiology, compensated vs. decompensated cirrhosis, clinical presentation, disease severity, distribution channels, treatment approaches, and region. Alcoholic cirrhosis leads the market, reflecting the widespread impact of excessive alcohol consumption on liver health. Decompensated cirrhosis prevails as the dominant clinical presentation, underlining the urgency for advanced treatment solutions. With its robust growth potential, autoimmune cirrhosis signals the increasing prevalence of autoimmune liver diseases. Hospitals and clinics emerge as the primary distribution channels, offering specialized care and comprehensive treatment options. Liver transplantation is prominent in the treatment landscape, addressing advanced cirrhosis cases, while medications, including antivirals and immunosuppressants, exhibit significant growth potential.

Rising incidences of liver diseases and cirrhosis, coupled with increasing alcohol consumption and obesity rates, are propelling the growth of the cirrhosis market on a global scale. Besides, advancements in diagnostic tools and imaging techniques enhance early detection and intervention, leading to better patient outcomes. The evolving landscape of personalized medicine and targeted therapies drives innovation in cirrhosis treatment approaches. Moreover, strategic collaborations between pharmaceutical companies and research organizations are promoting the development of novel treatment modalities.

The North American region dominates the cirrhosis market owing to advanced healthcare infrastructure and a high incidence of liver disease. The Asia-Pacific region is projected to offer substantial growth opportunities, driven by increasing healthcare investments, a growing patient pool, and rising awareness of liver diseases.

What Are The Main Drivers Of The Global Cirrhosis Market?

The global cirrhosis market is primarily driven by factors such as the emerging prevalence of liver diseases, including hepatitis and non-alcoholic fatty liver disease (NAFLD), major contributors to cirrhosis development. The growing geriatric population, escalating alcohol consumption, rising obesity rates, and the overall burden of lifestyle-related risk factors drive cirrhosis. Advances in medical technologies, improved diagnostics, and a growing emphasis on early disease detection and intervention also propel the demand for cirrhosis treatments. Furthermore, continuous R&D efforts to discover novel therapeutics and effective treatment options, coupled with rising healthcare expenditure and awareness, contribute to the market’s growth trajectory.

What Are The Major Challenges Faced By The Global Cirrhosis Market?

The global cirrhosis market faces several significant challenges, including the complex nature of cirrhosis and its underlying causes, which often involve multiple factors such as viral infections, alcohol consumption, obesity, and genetics. The lack of early symptoms in the initial stages of cirrhosis can lead to delayed diagnosis and treatment, posing challenges to disease management. Moreover, the limited availability of curative treatments for advanced stages of cirrhosis and the potential need for liver transplantation further complicate patient care. Regulatory hurdles in drug development and the high cost of treatment options further impede market growth.

What Are The Growth Opportunities In The Global Cirrhosis Market?

The global cirrhosis market presents several growth opportunities driven by medical research and technology advancements. Novel diagnostic tools, including non-invasive methods for early detection and monitoring of cirrhosis, offer the potential for improved patient outcomes. Collaborations between pharmaceutical companies and research institutions can foster drug discovery and development innovation, leading to more effective treatment options. Moreover, raising awareness about the risks of cirrhosis and the importance of early intervention can create a larger patient pool for diagnosis and treatment, thereby boosting market growth. Integrating digital health solutions and telemedicine platforms can enhance patient engagement and disease management, offering convenience and improved access to healthcare services.

Market Drivers

Several factors drive the global cirrhosis market. The following are the key drivers of the global cirrhosis market:

Advancements in Medical Research and Treatment

Continuous advancements in medical research and the development of innovative treatments contribute to the growth of the cirrhosis market. Expanding knowledge about liver pathophysiology, molecular mechanisms, and underlying causes of cirrhosis has led to identifying new therapeutic targets. Pharmaceutical companies are investing in research to discover novel drugs and therapies that can halt or reverse the progression of cirrhosis, improve liver function, and reduce associated complications.

Technological advancements in diagnostic tools, imaging techniques, and biomarker identification have enhanced cirrhosis’s early detection and monitoring, enabling timely intervention and personalized treatment strategies. These advancements drive the market’s growth by providing healthcare professionals with effective tools to manage cirrhosis patients and improve their quality of life.

Market Restraints

The global cirrhosis market faces challenges that may hinder its growth. These include the following:

Limited Treatment Options for Advanced Cirrhosis

Advanced stages of cirrhosis often come with severe complications such as portal hypertension, hepatic encephalopathy, ascites, and hepatocellular carcinoma. Despite medical advancements, treatment options for advanced cirrhosis remain limited. Liver transplantation is often considered the most effective treatment, but the availability of donor organs and the complex nature of the procedure pose challenges. Besides, not all patients are suitable candidates for transplantation due to various factors such as age, comorbidities, and limited access to healthcare facilities. The lack of curative therapies for advanced cirrhosis hinders treatment outcomes and patient quality of life.

Opportunities

The global cirrhosis market offers significant growth opportunities. These include the following:

Emerging New Therapies and Treatment Approaches

The field of cirrhosis research is witnessing the development of novel therapeutic approaches that target the underlying mechanisms of the disease. This includes investigating new drug candidates that aim to slow down fibrosis progression, reduce inflammation, and inhibit the development of complications. Innovative treatments such as antifibrotic agents, combination therapies, and regenerative medicine techniques can revolutionize cirrhosis management. Moreover, advancements in precision medicine and genetic profiling may enable the identification of patient-specific treatment strategies that maximize therapeutic efficacy and lower adverse effects.

Competitive Landscape

Cirrhosis Market Competiive Scenario

Key Players

The presence of key pharmaceutical companies, research institutions, and healthcare providers characterizes the competitive landscape of the global cirrhosis market. The following are some of the top market players and their market shares:

  • B. Braun Medical Inc
  • AstraZeneca
  • Histogen Inc
  • Stempeutics Research Pvt Ltd
  • Epic Research & Diagnostics Inc
  • Bayer AG
  • Sequana Medical AG
  • Pfizer Inc
  • Merck & Co. Inc
  • Novartis AG
  • Others

These companies focus on R&D activities to introduce innovative treatment options and therapies for cirrhosis patients. Strategic collaborations, partnerships, mergers, and acquisitions are common strategies to strengthen product portfolios and expand market reach. Investment in clinical trials and regulatory approvals is important in bringing new cirrhosis treatments to the market. Additionally, initiatives to raise awareness among healthcare professionals and patients about cirrhosis management contribute to market growth. The competitive dynamics also involve adopting advanced technologies, such as biomarker identification and precision medicine, to develop targeted therapies tailored to individual patient needs.

In September 2021, Merck (MSD) stated that its antibody Keytruda attained the primary objective of overall survival (OS) in Phase III KEYNOTE-394 clinical study in Asian patients with severe hepatocellular carcinoma (HCC), which is the most prevalent type of primary liver cancer.

In June 2021, Gilead Sciences, an American pharmaceutical company, submitted a plan to file for approval in the United States of ‘Hepcludex,’ an antiviral medication for hepatitis D virus (HDV). Hepcludex is an outstanding entry inhibitor registered in Russia as ‘Myrcludex B’ and has also been granted by the European Commission.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Summary of Key Findings

  • The global cirrhosis market is experiencing steady growth, driven by factors such as the rise in the prevalence of liver diseases, an increase in aging populations, and advancements in medical technology.
  • Market segmented by etiology, compensated vs. decompensated cirrhosis, clinical presentation, disease severity, distribution channels, treatment approaches, and region.
  • Alcoholic cirrhosis accounts for the largest market share, reflecting the major impact of alcohol-related liver damage.
  • Decompensated cirrhosis is prevalent, underscoring the need for advanced treatment options for patients with severe conditions.
  • The symptoms of decompensated cirrhosis, such as ascites, variceal bleeding, hepatic encephalopathy, and jaundice, drive treatment demand, emphasizing symptom management.
  • Liver transplantation is the leading treatment approach, while medications, including antivirals and immunosuppressants, show rapid growth potential.
  • The burden of cirrhosis is influenced by risk factors such as alcohol consumption, obesity, diabetes, viral hepatitis infections, and genetic predisposition.
  • Challenges in the cirrhosis market include limited awareness about the condition, late-stage diagnosis, and the complex interplay between different causes of cirrhosis, demanding a multi-faceted approach to management.
  • Regulatory agencies and healthcare organizations are working to establish standardized guidelines for cirrhosis management to ensure optimal patient care and consistent treatment approaches.

Future Outlook

  • The cirrhosis market is witnessing research and development efforts to discover novel therapeutic targets, including anti-fibrotic agents and immune-modulating drugs, to prevent disease progression and improve patient outcomes.
  • Emerging economies with growing healthcare infrastructure and rising awareness about liver health present opportunities for market expansion, as these regions experience an increasing burden of liver diseases.
  • Integrating digital health solutions and telemedicine platforms will likely facilitate remote monitoring and early intervention for cirrhosis patients, improving overall disease management.

Segmentation

  • By Etiology
    • Alcoholic Cirrhosis
    • Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis
    • Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C)
    • Autoimmune Cirrhosis
    • Genetic and Metabolic Disorders-Related Cirrhosis
  • By Compensated vs. Decompensated Cirrhosis
    • Compensated Cirrhosis
    • Decompensated Cirrhosis
  • By Clinical Presentation
    • Asymptomatic Cirrhosis
    • Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice)
  • By Disease Severity
    • Child-Pugh Score Class A
    • Child-Pugh Score Class B
    • Child-Pugh Score Class C
  • By Distribution Channels
    • Hospitals and Clinics
    • Retail Pharmacies
    • Specialty Pharmacies
  • By Treatment Approaches
    • Medications (Antivirals, Immunosuppressants)
    • Lifestyle Modifications (Diet, Alcohol Abstinence)
    • Surgical Interventions (Liver Transplantation)
  • By Region
    • North America
      • The U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • The U.K.
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • South-east Asia
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Argentina
      • Rest of Latin America
    • Middle East & Africa
      • GCC Countries
      • South Africa
      • Rest of the Middle East and Africa

Adjacent Markets

In the cirrhosis market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for cirrhosis market –

Cirrhosis Market adjacent market

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

 

2. Executive Summary

2.1. Market Snapshot: Global Cirrhosis Market

2.1.1. Global Cirrhosis Market, By Etiology

2.1.2. Global Cirrhosis Market, By Compensated vs. Decompensated Cirrhosis

2.1.3. Global Cirrhosis Market, By Clinical Presentation

2.1.4. Global Cirrhosis Market, By Disease Severity

2.1.5. Global Cirrhosis Market, By Distribution Channels

2.1.6. Global Cirrhosis Market, By Treatment Approaches

2.1.7. Global Cirrhosis Market, By Region

2.2. Insights from Primary Respondents

 

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Cirrhosis Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Cirrhosis Market Drivers

3.2.2. Cirrhosis Market Restraints

3.2.3. Cirrhosis Market Opportunities

3.2.4. Major Cirrhosis Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Etiology

3.5.2. Compensated vs. Decompensated Cirrhosis

3.5.3. Clinical Presentation

3.5.4. Disease Severity

3.5.5. Distribution Channels

3.5.6. Treatment Approaches

3.5.7. Geography

 

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Cirrhosis Market: Company Market Share, Value 2022

4.1.2. Global Cirrhosis Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Cirrhosis Market: Top 3 Company Market Share, Value 2022

4.2. Global Cirrhosis Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/ SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Cirrhosis Market

 

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

 

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

 

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Cirrhosis Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

 

8. Global Cirrhosis Market, By Etiology

8.1. Global Cirrhosis Market Overview, by Etiology

8.1.1. Global Cirrhosis Market Revenue Share, By Etiology, 2022 Vs 2030 (in %)

8.2. Alcoholic Cirrhosis

8.2.1. Global Cirrhosis Market, By Alcoholic Cirrhosis, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Alcoholic Cirrhosis

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis

8.3.1. Global Cirrhosis Market, By Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C)

8.4.1. Global Cirrhosis Market, By Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C), By Region, 2017-2030 (US$ Mn)

8.4.2. Market Dynamics for Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C)

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Autoimmune Cirrhosis

8.5.1. Global Cirrhosis Market, By Autoimmune Cirrhosis, By Region, 2017-2030 (US$ Mn)

8.5.2. Market Dynamics for Autoimmune Cirrhosis

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

8.6. Genetic and Metabolic Disorders-Related Cirrhosis

8.6.1. Global Cirrhosis Market, By Genetic and Metabolic Disorders-Related Cirrhosis, By Region, 2017-2030 (US$ Mn)

8.6.2. Market Dynamics for Genetic and Metabolic Disorders-Related Cirrhosis

8.6.2.1. Drivers

8.6.2.2. Restraints

8.6.2.3. Opportunities

8.6.2.4. Trends

 

9. Global Cirrhosis Market, By Compensated vs. Decompensated Cirrhosis

9.1. Global Cirrhosis Market Overview, by Compensated vs. Decompensated Cirrhosis

9.1.1. Global Cirrhosis Market Revenue Share, By Compensated vs. Decompensated Cirrhosis, 2022 Vs 2030 (in %)

9.2. Compensated Cirrhosis

9.2.1. Global Cirrhosis Market, By Compensated Cirrhosis, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Compensated Cirrhosis

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Decompensated Cirrhosis

9.3.1. Global Cirrhosis Market, By Decompensated Cirrhosis, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Decompensated Cirrhosis

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

 

10. Global Cirrhosis Market, By Clinical Presentation

10.1. Global Cirrhosis Market Overview, by Clinical Presentation

10.1.1. Global Cirrhosis Market Revenue Share, By Clinical Presentation, 2022 Vs 2030 (in %)

10.2. Asymptomatic Cirrhosis

10.2.1. Global Cirrhosis Market, By Asymptomatic Cirrhosis, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Asymptomatic Cirrhosis

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice)

10.3.1. Global Cirrhosis Market, By Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice), By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice)

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

 

11. Global Cirrhosis Market, By Disease Severity

11.1. Global Cirrhosis Market Overview, by Disease Severity

11.1.1. Global Cirrhosis Market Revenue Share, By Disease Severity, 2022 Vs 2030 (in %)

11.2. Child-Pugh Score Class A

11.2.1. Global Cirrhosis Market, By Child-Pugh Score Class A, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Child-Pugh Score Class A

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Child-Pugh Score Class B

11.3.1. Global Cirrhosis Market, By Child-Pugh Score Class B, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Child-Pugh Score Class B

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

11.4. Child-Pugh Score Class C

11.4.1. Global Cirrhosis Market, By Child-Pugh Score Class C, By Region, 2017-2030 (US$ Mn)

11.4.2. Market Dynamics for Child-Pugh Score Class C

11.4.2.1. Drivers

11.4.2.2. Restraints

11.4.2.3. Opportunities

11.4.2.4. Trends

 

12. Global Cirrhosis Market, By Distribution Channels

12.1. Global Cirrhosis Market Overview, by Distribution Channels

12.1.1. Global Cirrhosis Market Revenue Share, By Distribution Channels, 2022 Vs 2030 (in %)

12.2. Hospitals and Clinics

12.2.1. Global Cirrhosis Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)

12.2.2. Market Dynamics for Hospitals and Clinics

12.2.2.1. Drivers

12.2.2.2. Restraints

12.2.2.3. Opportunities

12.2.2.4. Trends

12.3. Specialty Pharmacies

12.3.1. Global Cirrhosis Market, By Specialty Pharmacies, By Region, 2017-2030 (US$ Mn)

12.3.2. Market Dynamics for Specialty Pharmacies

12.3.2.1. Drivers

12.3.2.2. Restraints

12.3.2.3. Opportunities

12.3.2.4. Trends

12.4. Retail Pharmacies

12.4.1. Global Cirrhosis Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

12.4.2. Market Dynamics for Retail Pharmacies

12.4.2.1. Drivers

12.4.2.2. Restraints

12.4.2.3. Opportunities

12.4.2.4. Trends

 

13. Global Cirrhosis Market, By Treatment Approaches

13.1. Global Cirrhosis Market Overview, by Treatment Approaches

13.1.1. Global Cirrhosis Market Revenue Share, By Treatment Approaches, 2022 Vs 2030 (in %)

13.2. Medications (Antivirals, Immunosuppressants)

13.2.1. Global Cirrhosis Market, By Medications (Antivirals, Immunosuppressants), By Region, 2017-2030 (US$ Mn)

13.2.2. Market Dynamics for Medications (Antivirals, Immunosuppressants)

13.2.2.1. Drivers

13.2.2.2. Restraints

13.2.2.3. Opportunities

13.2.2.4. Trends

13.3. Lifestyle Modifications (Diet, Alcohol Abstinence)

13.3.1. Global Cirrhosis Market, By Lifestyle Modifications (Diet, Alcohol Abstinence), By Region, 2017-2030 (US$ Mn)

13.3.2. Market Dynamics for Lifestyle Modifications (Diet, Alcohol Abstinence)

13.3.2.1. Drivers

13.3.2.2. Restraints

13.3.2.3. Opportunities

13.3.2.4. Trends

13.4. Surgical Interventions (Liver Transplantation)

13.4.1. Global Cirrhosis Market, By Surgical Interventions (Liver Transplantation), By Region, 2017-2030 (US$ Mn)

13.4.2. Market Dynamics for Surgical Interventions (Liver Transplantation)

13.4.2.1. Drivers

13.4.2.2. Restraints

13.4.2.3. Opportunities

13.4.2.4. Trends

 

14. Global Cirrhosis Market, By Region

14.1. Global Cirrhosis Market Overview, by Region

14.1.1. Global Cirrhosis Market, By Region, 2022 vs 2030 (in%)

14.2. Etiology

14.2.1. Global Cirrhosis Market, By Etiology, 2017-2030 (US$ Mn)

14.3. Compensated vs. Decompensated Cirrhosis

14.3.1. Global Cirrhosis Market, By Compensated vs. Decompensated Cirrhosis, 2017-2030 (US$ Mn)

14.4. Clinical Presentation

14.4.1. Global Cirrhosis Market, By Clinical Presentation, 2017-2030 (US$ Mn)

14.5. Disease Severity

14.5.1. Global Cirrhosis Market, By Disease Severity, 2017-2030 (US$ Mn)

14.6. Distribution Channels

14.6.1. Global Cirrhosis Market, By Distribution Channels, 2017-2030 (US$ Mn)

14.7. Treatment Approaches

14.7.1. Global Cirrhosis Market, By Treatment Approaches, 2017-2030 (US$ Mn)

 

15. North America Cirrhosis Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. North America Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. North America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. North America Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. North America Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. North America Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

15.6.1. Overview

15.6.2. SRC Analysis

15.7. North America Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

15.7.1. Overview

15.7.2. SRC Analysis

15.8. North America Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

15.8.1. North America Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

15.8.2. U.S.

15.8.3. Canada

15.8.4. Mexico

 

16. Europe Cirrhosis Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Europe Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Europe Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Europe Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Europe Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Europe Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

16.6.1. Overview

16.6.2. SRC Analysis

16.7. Europe Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

16.7.1. Overview

16.7.2. SRC Analysis

16.8. Europe Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

16.8.1. Europe Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

16.8.2. UK

16.8.3. France

16.8.4. Germany

16.8.5. Italy

16.8.6. Spain

16.8.7. Benelux

16.8.8. Russia

16.8.9. Rest of Europe

 

17. Asia Pacific Cirrhosis Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Asia Pacific Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Asia Pacific Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Asia Pacific Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Asia Pacific Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Asia Pacific Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

17.6.1. Overview

17.6.2. SRC Analysis

17.7. Asia Pacific Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

17.7.1. Overview

17.7.2. SRC Analysis

17.8. Asia Pacific Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

17.8.1. Asia Pacific Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

17.8.2. China

17.8.3. Japan

17.8.4. India

17.8.5. South Korea

17.8.6. South East Asia

17.8.7. Rest of Asia Pacific

 

18. Latin America Cirrhosis Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Latin America Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Latin America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Latin America Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Latin America Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Latin America Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

18.6.1. Overview

18.6.2. SRC Analysis

18.7. Latin America Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

18.7.1. Overview

18.7.2. SRC Analysis

18.8. Latin America Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

18.8.1. Latin America Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

18.8.2. Brazil

18.8.3. Argentina

18.8.4. Rest of Latin America

 

19. Middle East Cirrhosis Market Analysis

19.1. Overview

19.1.1. Market Dynamics for North America

19.1.1.1. Drivers

19.1.1.2. Restraints

19.1.1.3. Opportunities

19.1.1.4. Trends

19.2. Middle East Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

19.2.1. Overview

19.2.2. SRC Analysis

19.3. Middle East Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

19.3.1. Overview

19.3.2. SRC Analysis

19.4. Middle East Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

19.4.1. Overview

19.4.2. SRC Analysis

19.5. Middle East Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

19.5.1. Overview

19.5.2. SRC Analysis

19.6. Middle East Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

19.6.1. Overview

19.6.2. SRC Analysis

19.7. Middle East Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

19.7.1. Overview

19.7.2. SRC Analysis

19.8. Middle East Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

19.8.1. Middle East Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

19.8.2. UAE

19.8.3. Saudi Arabia

19.8.4. Rest of Middle East

 

20. Africa Cirrhosis Market Analysis

20.1. Overview

20.1.1. Market Dynamics for North America

20.1.1.1. Drivers

20.1.1.2. Restraints

20.1.1.3. Opportunities

20.1.1.4. Trends

20.2. Africa Cirrhosis Market, by Etiology, 2017-2030(US$ Mn)

20.2.1. Overview

20.2.2. SRC Analysis

20.3. Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2030(US$ Mn)

20.3.1. Overview

20.3.2. SRC Analysis

20.4. Africa Cirrhosis Market, by Clinical Presentation, 2017-2030(US$ Mn)

20.4.1. Overview

20.4.2. SRC Analysis

20.5. Africa Cirrhosis Market, by Disease Severity, 2017-2030(US$ Mn)

20.5.1. Overview

20.5.2. SRC Analysis

20.6. Africa Cirrhosis Market, by Distribution Channels, 2017-2030(US$ Mn)

20.6.1. Overview

20.6.2. SRC Analysis

20.7. Africa Cirrhosis Market, by Treatment Approaches, 2017-2030(US$ Mn)

20.7.1. Overview

20.7.2. SRC Analysis

20.8. Africa Cirrhosis Market, by Country, 2017-2030 (US$ Mn)

20.8.1. Middle East Cirrhosis Market, by Country, 2022 Vs 2030 (in%)

20.8.2. South Africa

20.8.3. Egypt

20.8.4. Rest of Africa

 

21. Company Profiles

21.1. B. Braun Medical Inc

21.1.1. Company Overview

21.1.2. Products/Services Portfolio

21.1.3. Geographical Presence

21.1.4. SWOT Analysis

21.1.5. Financial Summary

21.1.5.1. Market Revenue and Net Profit (2019-2022)

21.1.5.2. Business Segment Revenue Analysis

21.1.5.3. Geographical Revenue Analysis

21.2. AstraZeneca

21.3. Histogen Inc

21.4. Stempeutics Research Pvt Ltd

21.5. Epic Research & Diagnostics Inc

21.6. Bayer AG

21.7. Sequana Medical AG

21.8. Pfizer Inc

21.9. Merck & Co. Inc

21.10. Novartis AG

21.11. Others

22. Research Methodology

22.1. Research Methodology

22.2. Phase I – Secondary Research

22.3. Phase II – Data Modelling

22.3.1. Company Share Analysis Model

22.3.2. Revenue Based Modelling

22.4. Phase III – Primary Research

22.5. Research Limitations

22.5.1. Assumptions

 

List of Figures

FIG. 1 Global Cirrhosis Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Cirrhosis Market Segmentation

FIG. 4 Global Cirrhosis Market, by Etiology, 2022 (US$ Mn)

FIG. 5 Global Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2022 (US$ Mn)

FIG. 6 Global Cirrhosis Market, by Clinical Presentation, 2022 (US$ Mn)

FIG. 7 Global Cirrhosis Market, by Disease Severity, 2022 (US$ Mn)

FIG. 8 Global Cirrhosis Market, by Distribution Channels, 2022 (US$ Mn)

FIG. 9 Global Cirrhosis Market, by Treatment Approaches, 2022 (US$ Mn)

FIG. 10 Global Cirrhosis Market, by Geography, 2022 (US$ Mn)

FIG. 11 Attractive Investment Proposition, by Etiology, 2022

FIG. 12 Attractive Investment Proposition, by Compensated vs. Decompensated Cirrhosis, 2022

FIG. 13 Attractive Investment Proposition, by Clinical Presentation, 2022

FIG. 14 Attractive Investment Proposition, by Disease Severity, 2022

FIG. 15 Attractive Investment Proposition, by Distribution Channels, 2022

FIG. 16 Attractive Investment Proposition, by Treatment Approaches, 2022

FIG. 17 Attractive Investment Proposition, by Geography, 2022

FIG. 18 Global Market Share Analysis of Key Cirrhosis Market Manufacturers, 2022

FIG. 19 Global Market Positioning of Key Cirrhosis Market Manufacturers, 2022

FIG. 20 Global Cirrhosis Market Value Contribution, By Etiology, 2022 & 2030 (Value %)

FIG. 21 Global Cirrhosis Market, by Alcoholic Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Cirrhosis Market, by Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 23 Global Cirrhosis Market, by Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C), Value, 2017-2030 (US$ Mn)

FIG. 24 Global Cirrhosis Market, by Autoimmune Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Cirrhosis Market, by Genetic and Metabolic Disorders-Related Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Cirrhosis Market Value Contribution, By Compensated vs. Decompensated Cirrhosis, 2022 & 2030 (Value %)

FIG. 27 Global Cirrhosis Market, by Compensated Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 28 Global Cirrhosis Market, by Decompensated Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Cirrhosis Market Value Contribution, By Clinical Presentation, 2022 & 2030 (Value %)

FIG. 30 Global Cirrhosis Market, by Asymptomatic Cirrhosis, Value, 2017-2030 (US$ Mn)

FIG. 31 Global Cirrhosis Market, by Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice), Value, 2017-2030 (US$ Mn)

FIG. 32 Global Cirrhosis Market Value Contribution, By Disease Severity, 2022 & 2030 (Value %)

FIG. 33 Global Cirrhosis Market, by Child-Pugh Score Class A, Value, 2017-2030 (US$ Mn)

FIG. 34 Global Cirrhosis Market, by Child-Pugh Score Class B, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Cirrhosis Market, by Child-Pugh Score Class C, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Cirrhosis Market Value Contribution, By Distribution Channels, 2022 & 2030 (Value %)

FIG. 37 Global Cirrhosis Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)

FIG. 38 Global Cirrhosis Market, by Specialty Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 39 Global Cirrhosis Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 40 Global Cirrhosis Market Value Contribution, By Treatment Approaches, 2022 & 2030 (Value %)

FIG. 41 Global Cirrhosis Market, by Medications (Antivirals, Immunosuppressants), Value, 2017-2030 (US$ Mn)

FIG. 42 Global Cirrhosis Market, by Lifestyle Modifications (Diet, Alcohol Abstinence), Value, 2017-2030 (US$ Mn)

FIG. 43 Global Cirrhosis Market, by Surgical Interventions (Liver Transplantation), Value, 2017-2030 (US$ Mn)

FIG. 44 North America Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 45 U.S. Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 46 Canada Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 47 Mexico Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 48 Europe Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 49 Germany Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 50 France Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 51 U.K. Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 52 Italy Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 53 Spain Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 54 Benelux Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 55 Russia Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 56 Rest of Europe Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 57 Asia Pacific Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 58 China Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 59 Japan Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 60 India Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 61 South Korea Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 62 South-East Asia Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 63 Rest of Asia Pacific Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 64 Latin America Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 65 Brazil Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 66 Argentina Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 67 Rest of Latin America Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 68 Middle East Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 69 UAE Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 70 Saudi Arabia Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 71 Rest of Middle East Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 72 Africa Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 73 South Africa Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 74 Egypt Cirrhosis Market, 2017-2030 (US$ Mn)

FIG. 75 Rest of Africa Cirrhosis Market, 2017-2030 (US$ Mn)

 

List of Tables

TABLE 1 Market Snapshot: Global Cirrhosis Market

TABLE 2 Global Cirrhosis Market: Market Drivers Impact Analysis

TABLE 3 Global Cirrhosis Market: Market Restraints Impact Analysis

TABLE 4 Global Cirrhosis Market, by Competitive Benchmarking, 2022

TABLE 5 Global Cirrhosis Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Cirrhosis Market, by Key Strategies Analysis, 2022

TABLE 7 Global Cirrhosis Market, by Alcoholic Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Cirrhosis Market, by Alcoholic Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Cirrhosis Market, by Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Cirrhosis Market, by Non-Alcoholic Fatty Liver Disease (NAFLD) Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Cirrhosis Market, by Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C), By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Cirrhosis Market, by Viral Hepatitis-Related Cirrhosis (Hepatitis B, Hepatitis C), By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Cirrhosis Market, by Autoimmune Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Cirrhosis Market, by Autoimmune Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Cirrhosis Market, by Genetic and Metabolic Disorders-Related Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Cirrhosis Market, by Genetic and Metabolic Disorders-Related Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Cirrhosis Market, by Compensated Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Cirrhosis Market, by Compensated Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Cirrhosis Market, by Decompensated Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Cirrhosis Market, by Decompensated Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Cirrhosis Market, by Asymptomatic Cirrhosis, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Cirrhosis Market, by Asymptomatic Cirrhosis, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Cirrhosis Market, by Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice), By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Cirrhosis Market, by Symptoms of Decompensated Cirrhosis (Ascites, Variceal Bleeding, Hepatic Encephalopathy, Jaundice), By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Cirrhosis Market, by Child-Pugh Score Class A, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Cirrhosis Market, by Child-Pugh Score Class A, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Cirrhosis Market, by Child-Pugh Score Class B, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Cirrhosis Market, by Child-Pugh Score Class B, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Cirrhosis Market, by Child-Pugh Score Class C, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Cirrhosis Market, by Child-Pugh Score Class C, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Cirrhosis Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Cirrhosis Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Cirrhosis Market, by Specialty Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Cirrhosis Market, by Specialty Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Cirrhosis Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 36 Global Cirrhosis Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 37 Global Cirrhosis Market, by Medications (Antivirals, Immunosuppressants), By Region, 2017-2022 (US$ Mn)

TABLE 38 Global Cirrhosis Market, by Medications (Antivirals, Immunosuppressants), By Region, 2023-2030 (US$ Mn)

TABLE 39 Global Cirrhosis Market, by Lifestyle Modifications (Diet, Alcohol Abstinence), By Region, 2017-2022 (US$ Mn)

TABLE 40 Global Cirrhosis Market, by Lifestyle Modifications (Diet, Alcohol Abstinence), By Region, 2023-2030 (US$ Mn)

TABLE 41 Global Cirrhosis Market, by Surgical Interventions (Liver Transplantation), By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Cirrhosis Market, by Surgical Interventions (Liver Transplantation), By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 44 Global Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 45 Global Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 46 Global Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 47 Global Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 48 Global Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 49 Global Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 50 Global Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 51 Global Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 52 Global Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 53 Global Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 54 Global Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 55 Global Cirrhosis Market, by Region, 2017-2022 (US$ Mn)

TABLE 56 Global Cirrhosis Market, by Region, 2023-2030 (US$ Mn)

TABLE 57 North America Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 58 North America Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 59 North America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 60 North America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 61 North America Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 62 North America Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 63 North America Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 64 North America Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 65 North America Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 66 North America Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 67 North America Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 68 North America Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 69 North America Cirrhosis Market, by Country, 2017-2022 (US$ Mn)

TABLE 70 North America Cirrhosis Market, by Country, 2023-2030 (US$ Mn)

TABLE 71 United States Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 72 United States Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 73 United States Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 74 United States Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 75 United States Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 76 United States Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 77 United States Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 78 United States Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 79 United States Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 80 United States Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 81 United States Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 82 United States Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 83 Canada Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 84 Canada Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 85 Canada Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 86 Canada Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 87 Canada Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 88 Canada Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 89 Canada Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 90 Canada Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 91 Canada Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 92 Canada Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 93 Canada Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 94 Canada Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 95 Mexico Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 96 Mexico Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 97 Mexico Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 98 Mexico Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 99 Mexico Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 100 Mexico Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 101 Mexico Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 102 Mexico Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 103 Mexico Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 104 Mexico Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 105 Mexico Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 106 Mexico Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 107 Europe Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 108 Europe Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 109 Europe Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 110 Europe Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 111 Europe Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 112 Europe Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 113 Europe Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 114 Europe Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 115 Europe Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 116 Europe Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 117 Europe Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 118 Europe Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 119 Europe Cirrhosis Market, by Country, 2017-2022 (US$ Mn)

TABLE 120 Europe Cirrhosis Market, by Country, 2023-2030 (US$ Mn)

TABLE 121 Germany Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 122 Germany Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 123 Germany Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 124 Germany Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 125 Germany Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 126 Germany Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 127 Germany Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 128 Germany Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 129 Germany Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 130 Germany Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 131 Germany Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 132 Germany Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 133 France Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 134 France Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 135 France Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 136 France Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 137 France Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 138 France Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 139 France Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 140 France Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 141 France Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 142 France Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 143 France Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 144 France Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 145 United Kingdom Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 146 United Kingdom Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 147 United Kingdom Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 148 United Kingdom Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 149 United Kingdom Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 150 United Kingdom Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 151 United Kingdom Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 152 United Kingdom Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 153 United Kingdom Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 154 United Kingdom Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 155 United Kingdom Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 156 United Kingdom Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 157 Italy Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 158 Italy Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 159 Italy Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 160 Italy Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 161 Italy Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 162 Italy Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 163 Italy Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 164 Italy Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 165 Italy Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 166 Italy Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 167 Italy Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 168 Italy Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 169 Spain Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 170 Spain Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 171 Spain Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 172 Spain Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 173 Spain Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 174 Spain Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 175 Spain Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 176 Spain Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 177 Spain Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 178 Spain Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 179 Spain Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 180 Spain Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 181 Benelux Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 182 Benelux Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 183 Benelux Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 184 Benelux Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 185 Benelux Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 186 Benelux Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 187 Benelux Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 188 Benelux Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 189 Benelux Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 190 Benelux Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 191 Benelux Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 192 Benelux Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 193 Russia Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 194 Russia Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 195 Russia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 196 Russia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 197 Russia Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 198 Russia Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 199 Russia Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 200 Russia Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 201 Russia Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 202 Russia Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 203 Russia Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 204 Russia Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 205 Rest of Europe Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 206 Rest of Europe Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 207 Rest of Europe Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 208 Rest of Europe Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 209 Rest of Europe Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 210 Rest of Europe Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 211 Rest of Europe Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 212 Rest of Europe Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 213 Rest of Europe Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 214 Rest of Europe Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 215 Rest of Europe Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 216 Rest of Europe Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 217 Asia Pacific Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 218 Asia Pacific Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 219 Asia Pacific Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 220 Asia Pacific Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 221 Asia Pacific Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 222 Asia Pacific Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 223 Asia Pacific Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 224 Asia Pacific Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 225 Asia Pacific Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 226 Asia Pacific Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 227 Asia Pacific Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 228 Asia Pacific Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 229 China Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 230 China Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 231 China Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 232 China Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 233 China Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 234 China Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 235 China Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 236 China Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 237 China Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 238 China Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 239 China Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 240 China Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 241 Japan Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 242 Japan Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 243 Japan Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 244 Japan Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 245 Japan Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 246 Japan Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 247 Japan Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 248 Japan Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 249 Japan Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 250 Japan Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 251 Japan Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 252 Japan Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 253 India Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 254 India Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 255 India Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 256 India Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 257 India Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 258 India Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 259 India Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 260 India Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 261 India Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 262 India Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 263 India Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 264 India Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 265 South Korea Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 266 South Korea Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 267 South Korea Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 268 South Korea Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 269 South Korea Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 270 South Korea Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 271 South Korea Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 272 South Korea Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 273 South Korea Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 274 South Korea Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 275 South Korea Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 276 South Korea Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 277 South-East Asia Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 278 South-East Asia Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 279 South-East Asia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 280 South-East Asia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 281 South-East Asia Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 282 South-East Asia Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 283 South-East Asia Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 284 South-East Asia Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 285 South-East Asia Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 286 South-East Asia Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 287 South-East Asia Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 288 South-East Asia Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 289 Rest of Asia Pacific Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 290 Rest of Asia Pacific Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 291 Rest of Asia Pacific Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 292 Rest of Asia Pacific Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 293 Rest of Asia Pacific Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 294 Rest of Asia Pacific Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 295 Rest of Asia Pacific Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 296 Rest of Asia Pacific Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 297 Rest of Asia Pacific Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 298 Rest of Asia Pacific Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 299 Rest of Asia Pacific Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 300 Rest of Asia Pacific Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 301 Latin America Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 302 Latin America Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 303 Latin America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 304 Latin America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 305 Latin America Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 306 Latin America Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 307 Latin America Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 308 Latin America Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 309 Latin America Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 310 Latin America Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 311 Latin America Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 312 Latin America Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 313 Brazil Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 314 Brazil Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 315 Brazil Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 316 Brazil Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 317 Brazil Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 318 Brazil Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 319 Brazil Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 320 Brazil Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 321 Brazil Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 322 Brazil Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 323 Brazil Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 324 Brazil Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 325 Argentina Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 326 Argentina Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 327 Argentina Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 328 Argentina Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 329 Argentina Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 330 Argentina Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 331 Argentina Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 332 Argentina Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 333 Argentina Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 334 Argentina Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 335 Argentina Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 336 Argentina Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 337 Rest of Latin America Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 338 Rest of Latin America Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 339 Rest of Latin America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 340 Rest of Latin America Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 341 Rest of Latin America Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 342 Rest of Latin America Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 343 Rest of Latin America Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 344 Rest of Latin America Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 345 Rest of Latin America Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 346 Rest of Latin America Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 347 Rest of Latin America Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 348 Rest of Latin America Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 349 Middle East Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 350 Middle East Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 351 Middle East Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 352 Middle East Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 353 Middle East Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 354 Middle East Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 355 Middle East Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 356 Middle East Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 357 Middle East Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 358 Middle East Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 359 Middle East Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 360 Middle East Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 361 UAE Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 362 UAE Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 363 UAE Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 364 UAE Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 365 UAE Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 366 UAE Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 367 UAE Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 368 UAE Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 369 UAE Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 370 UAE Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 371 UAE Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 372 UAE Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 373 Saudi Arabia Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 374 Saudi Arabia Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 375 Saudi Arabia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 376 Saudi Arabia Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 377 Saudi Arabia Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 378 Saudi Arabia Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 379 Saudi Arabia Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 380 Saudi Arabia Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 381 Saudi Arabia Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 382 Saudi Arabia Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 383 Saudi Arabia Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 384 Saudi Arabia Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 385 Rest of Middle East Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 386 Rest of Middle East Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 387 Rest of Middle East Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 388 Rest of Middle East Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 389 Rest of Middle East Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 390 Rest of Middle East Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 391 Rest of Middle East Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 392 Rest of Middle East Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 393 Rest of Middle East Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 394 Rest of Middle East Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 395 Rest of Middle East Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 396 Rest of Middle East Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 397 Africa Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 398 Africa Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 399 Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 400 Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 401 Africa Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 402 Africa Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 403 Africa Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 404 Africa Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 405 Africa Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 406 Africa Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 407 Africa Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 408 Africa Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 409 South Africa Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 410 South Africa Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 411 South Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 412 South Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 413 South Africa Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 414 South Africa Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 415 South Africa Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 416 South Africa Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 417 South Africa Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 418 South Africa Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 419 South Africa Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 420 South Africa Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 421 Egypt Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 422 Egypt Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 423 Egypt Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 424 Egypt Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 425 Egypt Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 426 Egypt Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 427 Egypt Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 428 Egypt Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 429 Egypt Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 430 Egypt Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 431 Egypt Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 432 Egypt Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

TABLE 433 Rest of Africa Cirrhosis Market, by Etiology, 2017-2022 (US$ Mn)

TABLE 434 Rest of Africa Cirrhosis Market, by Etiology, 2023-2030 (US$ Mn)

TABLE 435 Rest of Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2017-2022 (US$ Mn)

TABLE 436 Rest of Africa Cirrhosis Market, by Compensated vs. Decompensated Cirrhosis, 2023-2030 (US$ Mn)

TABLE 437 Rest of Africa Cirrhosis Market, by Clinical Presentation, 2017-2022 (US$ Mn)

TABLE 438 Rest of Africa Cirrhosis Market, by Clinical Presentation, 2023-2030 (US$ Mn)

TABLE 439 Rest of Africa Cirrhosis Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 440 Rest of Africa Cirrhosis Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 441 Rest of Africa Cirrhosis Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 442 Rest of Africa Cirrhosis Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 443 Rest of Africa Cirrhosis Market, by Treatment Approaches, 2017-2022 (US$ Mn)

TABLE 444 Rest of Africa Cirrhosis Market, by Treatment Approaches, 2023-2030 (US$ Mn)

Frequently asked questions

What is the current size of the global cirrhosis market?

The global cirrhosis market was valued at USD 658.9 Million in 2022.

What is the expected growth rate of the cirrhosis market between 2023 and 2030?

The cirrhosis market is expected to grow at a CAGR of 4.2% between 2023 and 2030, reaching USD 915.71 Million in 2030.

Which segment is leading the market share in terms of etiology?

Alcoholic cirrhosis is the leading segment by etiology, holding over 35% share in value in 2022.

Which distribution channel segment governs the global demand for cirrhosis?

The hospitals and clinics segment governs the global demand for cirrhosis, holding a massive share of over 44% in 2022.

Which treatment approaches segment will post the highest CAGR in the forecast period?

The medications (antivirals, immunosuppressants) segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the cirrhosis industry?

North America is fueling the growth of the cirrhosis industry, with over one-third share in 2022.

Who are the major players in the global cirrhosis market?

The top players include B. Braun Medical Inc., AstraZeneca, Histogen Inc., Stempeutics Research Pvt Ltd, Epic Research & Diagnostics Inc, Bayer AG, Sequana Medical AG, Pfizer Inc., Merck & Co. Inc., Novartis AG, and Others.

What are the major market drivers of the cirrhosis industry?

The major market drivers are the increasing prevalence of liver diseases, a growing aging population, and advancements in medical technologies and treatments.

What are the major market restraints of the cirrhosis industry?

The major market restraints of the cirrhosis industry encompass the high cost of treatments, limited availability of effective therapies, and challenges related to early diagnosis and disease management.

What are the major market opportunities of the cirrhosis industry?

The major market opportunities in the cirrhosis industry involve the development of novel therapeutic interventions, expanding healthcare infrastructure in emerging markets, and increasing awareness about liver health and prevention strategies.

Fibroscan Market

Published:
Report ID: 49330

Primary Hepatocyte Market

Published:
Report ID: 34377

Hepatic Encephalopathy Market

Published:
Report ID: 33664

Primary Biliary Cholangitis (PBC) Treatment Market

Published:
Report ID: 11571

GMP Cell Therapy Consumables Market

Published:
Report ID: 59958

Flea Tick and Heartworm Products Market

Published:
Report ID: 59921

Medical Engineered Materials Market

Published:
Report ID: 59833

Active Pharmaceutical Ingredient Market

Published:
Report ID: 1270

Pharmaceutical CDMO Services Market

Published:
Report ID: 9407

Oncology Biosimilars Market

Published:
Report ID: 7738

Vasculitis Treatment Market

Published:
Report ID: 11489

Topical Drug Delivery Market

Published:
Report ID: 59463

Radiodermatitis Market

Published:
Report ID: 8730

Aromatherapy Market

Published:
Report ID: 1785

Human Microbiome Market

Published:
Report ID: 7321

Strontium Nitrate Market

Published:
Report ID: 59322

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$3699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$4699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$6699

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN